Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.

Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I, McAllister SS.

Breast Cancer Res. 2017 Mar 6;19(1):23. doi: 10.1186/s13058-017-0815-8.

2.

Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit.

Zekri J, Farag K.

J Bone Oncol. 2016 Jun 2;5(4):159-162. doi: 10.1016/j.jbo.2016.05.007. eCollection 2016 Nov.

3.

The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.

Amin S, Boffetta P, Lucas AL.

Gut Liver. 2016 Sep 15;10(5):665-71. doi: 10.5009/gnl15451. Review.

4.

The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.

Kim HA, Ahn SH, Nam SJ, Park S, Ro J, Im SA, Jung YS, Yoon JH, Hur MH, Choi YJ, Lee SJ, Jeong J, Cho SH, Kim SY, Lee MH, Kim LS, Moon BI, Kim TH, Park C, Kim SJ, Jung SH, Park H, Gwak GH, Kang SH, Kim JG, Kim J, Choi SY, Lim CW, Kim D, Yoo Y, Song YJ, Kang YJ, Jung SS, Shin HJ, Lee KJ, Han SH, Lee ES, Han W, Kim HJ, Noh WC.

BMC Cancer. 2016 May 19;16:319. doi: 10.1186/s12885-016-2354-6.

6.

Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.

Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V, Cassibba S, Cesareo R, Chiodini I, Francucci CM, Gianotti L, Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A, Vignali E, Rochira V, Zini M.

J Endocrinol Invest. 2016 Jul;39(7):807-34. doi: 10.1007/s40618-016-0434-8. Epub 2016 Mar 11.

7.

The anti-tumour effects of zoledronic acid.

Zekri J, Mansour M, Karim SM.

J Bone Oncol. 2014 Jan 15;3(1):25-35. doi: 10.1016/j.jbo.2013.12.001. eCollection 2014 Mar. Review.

8.

Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases.

Kim HJ, Park TJ, Ahn KM.

Maxillofac Plast Reconstr Surg. 2016 Feb 1;38(1):6. doi: 10.1186/s40902-016-0052-6. eCollection 2016 Dec.

9.

Managing breast cancer in younger women: challenges and solutions.

Ademuyiwa FO, Cyr A, Ivanovich J, Thomas MA.

Breast Cancer (Dove Med Press). 2015 Dec 21;8:1-12. doi: 10.2147/BCTT.S68848. eCollection 2016. Review.

10.

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.

Paterson AH, Shea-Budgell MA.

J Clin Med. 2013 Dec 17;2(4):283-301. doi: 10.3390/jcm2040283. Review.

11.

Cancer Treatment-Induced Bone Loss in women with breast cancer.

Hadji P.

Bonekey Rep. 2015 May 20;4:692. doi: 10.1038/bonekey.2015.60. eCollection 2015. Review.

12.

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, Eisen A.

Curr Oncol. 2015 Mar;22(Suppl 1):S95-S113. doi: 10.3747/co.22.2326. Review.

13.

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.

Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S.

Osteoporos Int. 2015 Jun;26(6):1857-64. doi: 10.1007/s00198-015-3100-7. Epub 2015 Mar 20.

14.
15.

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sasai K, Fujimoto T.

Breast Cancer. 2016 May;23(3):499-509. doi: 10.1007/s12282-015-0593-z. Epub 2015 Feb 6.

16.

Management options of breast cancer related osteoporosis.

Becorpi A, Sisti G, Sorbi F, Malosso ER, Guaschino S.

Clin Cases Miner Bone Metab. 2014 May;11(2):110-3. Review.

17.

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Hosford SR, Miller TW.

Pharmgenomics Pers Med. 2014 Aug 6;7:203-15. doi: 10.2147/PGPM.S52762. eCollection 2014. Review.

18.

Aromatase inhibitors-induced bone loss in early breast cancer.

Body JJ.

Bonekey Rep. 2012 Oct 3;1:201. doi: 10.1038/bonekey.2012.201. eCollection 2012.

19.

Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, Gorenstein DG, Liu X, Ferrari M, Shen H.

J Control Release. 2014 Aug 10;187:22-9. doi: 10.1016/j.jconrel.2014.04.057. Epub 2014 May 10.

Supplemental Content

Support Center